Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 13, 2017 | Ordinary Shares (25p) | £16.3903 | 315 shares | London Stock Exchange (XLON) |
Note: The total volume of 315 shares is the aggregate of individual transactions by nine executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ordinary shares by executives following the re-investment of dividends paid on April 13, 2017, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved nine senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Share Price: The execution price for all transactions was uniform at £16.3903 per share.
- Scope: The filing does not provide data on the company's overall financial performance for the period.